Comparative study of an angiotensin-II analog and a converting enzyme inhibitor
Reads0
Chats0
TLDR
The effects of an angiotensin-II analog (saralasin) and of a converting enzyme inhibitor (captopril, oral) were compared in 12 sodium-depleted patients with hypertension to suggest that the antihypertensive action of captopril is not based solely on the inhibition of AII formation, but also the agonistic effect of saralasin has to be considered.About:
This article is published in Kidney International.The article was published on 1980-05-01 and is currently open access. It has received 23 citations till now. The article focuses on the topics: Saralasin & Angiotensin II.read more
Citations
More filters
Book ChapterDOI
Angiotensin converting enzyme (ACE) inhibitors
TL;DR: Angiotensin converting enzyme inhibitors represent a new class of agents which were designed to retain only that unique property and results in the significant reduction of elevated blood pressure of various etiologies and in the amelioration of symptoms associated with congestive heart failure resistant to digitalis glycosides and diuretics.
Journal ArticleDOI
Hypertension in chronic renal disease
TL;DR: A 32-year-old man was admitted to the Instituto Nacional de Ia Nutricion Salvador Zubiran for evaluation of chronic renal failure and severe hypertension with a history of frequent episodes of pharyngitis during childhood.
Journal ArticleDOI
Response of the systemic and pulmonary circulation to converting-enzyme inhibition (captopril) at rest and during exercise in hypertensive patients.
TL;DR: The data indicate that the action of captopril is characterized by arteriolar and possibly venous dilatation both at rest and during exercise, however, Pulmonary vascular resistance is not affected.
Journal ArticleDOI
Hemodynamic Effects of Captopril in Essential Hypertension, Renovascular Hypertension and Cardiac Failure: Correlations With Short- and Long-Term Effects on Plasma Renin
G. J. Wenting,J. H. B. de Bruyn,A. J. Man In 'T Veld,Arend J.J. Woittiez,Frans H.M. Derkx,Maarten A.D.H. Schalekamp +5 more
TL;DR: Blood pressure responses to long-term captopril therapy in essential and in renovascular hypertension were similar and, as with short-term treatment, changes in blood pressure were largely determined by changes in peripheral resistance.
Journal ArticleDOI
Comparison of renin and converting enzyme inhibition in sodium-deficient dogs.
E H Blaine,B J Nelson,A A Seymour,T W Schorn,Charles S. Sweet,E E Slater,Jürg Nussberger,J Boger +7 more
TL;DR: It is indicated that enalaprilat is a more effective hypotensive agent in Nadeficient dogs than SCRIP and actions in addition to inhibition of the formation of circulating angiotensin II are suggested.
References
More filters
Journal ArticleDOI
Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents
TL;DR: A hypothetical model of the active site of angiotensin-converting enzyme, based on known chemical and kinetic properties of the enzyme, has enabled a new class of potent and specific inhibitors, carboxyalkanoyl and mercaptoalkanoysl derivatives of proline, to be designed.
Journal ArticleDOI
Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in Man
Haralambos Gavras,Hans R. Brunner,Gustave A. Turini,Glenn R. Kershaw,Charles P. Tifft,Sergio Cuttelod,Irene Gavras,Robert A. Vukovich,Doris N. McKinstry +8 more
TL;DR: SQ 14225 is a promising new antihypertensive agent, effective in patients refractory to traditional medical therapy, and the exact mechanisms contributing to the blood-pressure-lowering effect of this agent remain unclear.
Journal ArticleDOI
Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients.
David B. Case,Steven A. Atlas,John H. Laragh,Jean E. Sealey,Patricia A. Sullivan,Doris N. McKinstry +5 more
TL;DR: Examination of the renin-lowering effect of β-adrenergic blockade in patients with essential and malignant hypertension found that propranolol in low to moderate doses lowers blood pressure in high an normal renin forms of hypertension but does not significantly lowerBlood pressure in low renin hypertensive pateints.
Journal ArticleDOI
Oral Angiotensin-Converting Enzyme Inhibitor in Long-Term Treatment of Hypertensive Patients
Hans R. Brunner,Haralambos Gavras,Bernard Waeber,Glen R. Kershaw,Gustave A. Turini,Robert A. Vukovich,Doris N. McKinstry,Irene Gavras +7 more
TL;DR: The results indicate that chronic inhibition of the angiotensin-converting enzyme with an orally active compound offers a new, efficient, and well-tolerated approach to the treatment of hypertension.
Journal ArticleDOI
A specific orally active inhibitor of angiotensin-converting enzyme in man
TL;DR: An orally active inhibitor of the angiotensin-converting enzyme, SQ 14,225 (D-2-methyl-3-mercaptopropanoly-L-proline), was administered to fourteen normal male volunteers to evaluate its safety and efficacy in inhibiting pressor responses to exogenous angiotsin I.